Related Experiment Video
Updated: Mar 25, 2026
09:41
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
9.2K
Risk Stratification in Multiple Myeloma.
Melissa Gaik-Ming Ooi1, Sanjay de Mel2, Wee Joo Chng2
1, 1E Kent Ridge Road, NUHS Tower Block Level 7, Singapore, 119228, Singapore. Melissa_ooi@nuhs.edu.sg.
Current Hematologic Malignancy Reports
|February 18, 2016
Summary
The Revised International Staging System (R-ISS) offers more comprehensive risk stratification for multiple myeloma than the older International Staging System (ISS). R-ISS incorporates key variables like genetics and age, improving patient outcome prediction.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Multiple myeloma prognosis relies on numerous variables, making accurate risk stratification challenging.
- The International Staging System (ISS) is widely used but lacks crucial prognostic factors like genetics and age.
- Existing staging systems require enhancement to fully capture patient risk in multiple myeloma.
Purpose of the Study:
- To review current prognostic variables in multiple myeloma.
- To evaluate the significance of these variables in patient risk stratification.
- To advocate for the adoption of the Revised International Staging System (R-ISS) as a superior predictive tool.
Main Methods:
- Literature review of prognostic variables in multiple myeloma.
- Comparative analysis of the International Staging System (ISS) and the Revised International Staging System (R-ISS).
- Discussion of the clinical utility and predictive power of different staging systems.
Main Results:
- Identified numerous prognostic variables in multiple myeloma, with varying degrees of significance.
- Highlighted the limitations of the International Staging System (ISS) in incorporating essential prognostic factors.
- Demonstrated that the Revised International Staging System (R-ISS) provides a more comprehensive and predictive framework.
Conclusions:
- The Revised International Staging System (R-ISS) is a more advanced and accurate tool for multiple myeloma risk stratification.
- R-ISS overcomes the limitations of ISS by integrating critical variables such as genetics and age.
- Clinical utilization of R-ISS is recommended for improved patient management and outcome prediction in multiple myeloma.
